PUBLISHER: DataM Intelligence | PRODUCT CODE: 1272773
PUBLISHER: DataM Intelligence | PRODUCT CODE: 1272773
Global Scleroderma Market - 2023-2030
Market Overview
The global scleroderma market reached USD 2,169.4 million in 2022 and is projected to witness to reach up to USD 3,468.3 million by 2030. The scleroderma market is expected to exhibit a CAGR of 6.2% during the forecast period (2023-2030). The key market players are adopting various strategies such as product approvals, acquisitions, partnerships, and new launches to increase product reach and strengthen their product portfolios, to enter or expand their business offerings and competitiveness in the scleroderma market.
For instance, on March 11, 2022, Pfizer Inc. completed its acquisition of Arena Pharmaceuticals, a clinical-stage company developing innovative potential therapies for treating several immuno-inflammatory diseases. Arena's pipeline includes two development-stage cardiovascular assets: temanogrel for microvascular obstruction and Raynaud's phenomenon secondary to systemic sclerosis and APD418 for acute heart failure.
Scleroderma is an autoimmune connective tissue and rheumatic disorder that induces inflammation in the skin and other organs of the body. Though it is a rare disorder, the aggressive nature and growing prevalence among other factors are boosting the global scleroderma market growth.
Market Dynamics
The research funding and investments are expected to drive the scleroderma market growth during the forecast period
The increasing funding and investment activities for scleroderma treatment research are expected to boost the global scleroderma market over the forecast period. For instance, the National Scleroderma Foundation secured research grants in 2022, allowing double their research funding to USD 2.4 million. Additionally, in February 2023, the National Scleroderma Foundation announced its annual grant awards totaling USD 1.6 million to support identifying and designing new treatments and a cure for scleroderma.
The growing initiatives in the fight against scleroderma provide the market with growth opportunities
The increasing initiatives to spread awareness and provide support to scleroderma patients are presenting the global scleroderma market with lucrative growth opportunities in the forthcoming years. For instance, in January 2023, the HealthWell Foundation, an autonomous non-profit organization that delivers a financial lifeline for poorly insured Americans, extended a new budget to deliver financial help to individuals living with systemic sclerosis with interstitial lung disease (SSc-ILD). Via the new budget, HealthWell intends to deliver up to USD 9,000 in medication copayment or insurance premium subsidy to suitable patients with annual family earnings up to 500% of the federal poverty level for managing their disorder.
Russia-Ukraine Conflict Analysis
The Russia-Ukraine war has negatively impacted the market and because of the conflict-induced situation, many research studies have been delayed directly impacting the global scleroderma market growth. For instance, according to a new article published in April 2022, Russia's war in Ukraine has affected trials of Roche Holding AG's latest testing of multiple sclerosis medication, as physicians rush to transfer patients who have become refugees to unexplored treatment bases.
Global Recession Impact Analysis
The healthcare industry is not completely immune to recession, as healthcare institutions thought firings and employing freezes during past financial downturns. That stated, the industry does cope finer than other sectors because of its essential nature. However, the danger of recession threatens the market as inflation persists increasing. The elevated extent of tension about the persistent recession could hold a substantial influence on the scleroderma market over the following few years.
Artificial Intelligence Impact Analysis
The perspective benefits offered by AI in scleroderma diagnosis and treatment are estimated to have a positive influence on the global scleroderma market. For instance, the open-source computer algorithm Vision Transformer (ViT) could catch anomalies on nail fold capillaroscopy (NFC) pictures, according to conclusions submitted at the annual meeting of the American College of Rheumatology ACR Convergence 2022.
Segment Analysis
The global scleroderma market is segmented based on treatment, disease type, end users, and region.
The systemic sclerosis segment is estimated to hold the largest global scleroderma market share by 2030
Owing to the growing cases and new drug approvals, systemic sclerosis segment is estimated to hold a market share of around 74.6% of the entire scleroderma market by 2030. For instance, according to the University of Michigan Health, systemic sclerosis occurs in around 30 persons per million population per year and there are an estimated 125,000 active cases in the U.S. and perhaps 2.5 million worldwide. It is the most fatal of all rheumatologic diseases. Also, in April 2022, aTyr Pharma, Inc., a public biotherapeutics company obtained USFDA clearance for efzofitimod utilized in the treatment of systemic sclerosis.
Geographical Analysis
Europe is estimated to hold the second-largest share of the global scleroderma market during the forecast period
Owing to the presence of a better action plan and its execution in this region for the scleroderma condition, the Europe region is estimated to hold about 27.6% of the global scleroderma market by 2030. For instance, over the duration of 2022, the England Rare Diseases Framework Delivery Group has persisted to assemble regularly to harmonize the delivery of England's action strategies. The group gets together publicly supported delivery members and agents of the rare condition patient and clinician communities, to observe the delivery of existing commitments, and settle on the scope of prospective action strategies.
Competitive Landscape
The major global players in the market include Pfizer, Inc., Sanofi, GlaxoSmithKline plc, Cumberland Pharmaceuticals, Inc., Actelion Pharmaceuticals, Inc. (Johnson&Johnson), Boehringer Ingelheim International GmbH (C.H. Boehringer Sohn Ag & Co. KG), Corbus Pharmaceuticals Holdings, Inc., Bayer AG, Gilead Sciences, Inc. and Allergan, Inc. (Abbvie) are among others.
Why Purchase the Report?
- To visualize the global scleroderma market segmentation based on product, application, and region, as well as understand key commercial assets and players.
- Identify commercial opportunities by analyzing trends and co-development.
- Excel data sheet with numerous data points of scleroderma market-level with all segments.
- PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
- Product mapping available as Excel consisting of key products of all the major players.
The global scleroderma market report would provide approximately 53 tables, 54 figures, and 195 Pages.
Target Audience 2023
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies
Table of Contents
1. Methodology and Scope
- 1.1. Research Methodology
- 1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
- 3.1. Snippet by Treatment
- 3.2. Snippet by Disease Type
- 3.3. Snippet by End User
- 3.4. Snippet by Region
4. Dynamics
- 4.1. Impacting Factors
- 4.1.1. Drivers
- 4.1.1.1. Increasing Product Approvals
- 4.1.1.2. Increasing Fundings and Investments
- 4.1.2. Restraints
- 4.1.2.1. Drug Side Effects
- 4.1.3. Opportunity
- 4.1.3.1. Increasing Awareness
- 4.1.4. Impact Analysis
- 4.1.1. Drivers
5. Industry Analysis
- 5.1. Porter's Five Forces Analysis
- 5.2. Supply Chain Analysis
- 5.3. Unmet Needs
- 5.4. Regulatory Analysis
6. COVID-19 Analysis
- 6.1. Analysis of COVID-19
- 6.1.1. Before COVID-19 Scenario
- 6.1.2. Present COVID-19 Scenario
- 6.1.3. Post COVID-19 or Future Scenario
- 6.2. Pricing Dynamics Amid COVID-19
- 6.3. Demand-Supply Spectrum
- 6.4. Government Initiatives Related to the Market During the Pandemic
- 6.5. Manufacturers' Strategic Initiatives
- 6.6. Conclusion
7. Russia-Ukraine Conflict Analysis
8. Global Recession Analysis
9. Artificial Intelligence Impact Analysis
10. By Treatment
- 10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
- 10.1.2. Market Attractiveness Index, By Treatment
- 10.2. Medication
- 10.2.1. Introduction
- 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 10.2.3. Immunosuppressors
- 10.2.4. Phosphodiesterase 5 Inhibitors - PHA
- 10.2.5. Endothelin Receptor Antagonists (ERA)
- 10.2.6. Calcium Channel Blockers (CCBs)
- 10.2.7. Prostacyclin Analogues (PA)
- 10.2.8. Analgesics
- 10.2.9. Others
- 10.3. Surgery & Other Therapies
11. By Disease Type
- 11.1. Introduction
- 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
- 11.1.2. Market Attractiveness Index, By Disease Type
- 11.2. Systemic scleroderma*
- 11.2.1. Introduction
- 11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 11.2.3. Limited Cutaneous Systemic Sclerosis Syndrome
- 11.2.4. Diffuse Systemic Sclerosis
- 11.2.5. Sine Sclerosis
- 11.3. Localized scleroderma
- 11.3.1. Morphea
- 11.3.2. Linear Scleroderma
12. By End User
- 12.1. Introduction
- 12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 12.1.2. Market Attractiveness Index, By End User
- 12.2. Hospitals*
- 12.2.1. Introduction
- 12.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 12.3. Retail and Online Pharmacies
- 12.4. Others
13. By Region
- 13.1. Introduction
- 13.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 13.1.2. Market Attractiveness Index, By Region
- 13.2. North America
- 13.2.1. Introduction
- 13.2.2. Key Region-Specific Dynamics
- 13.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
- 13.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
- 13.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 13.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 13.2.6.1. The U.S.
- 13.2.6.2. Canada
- 13.2.6.3. Mexico
- 13.3. Europe
- 13.3.1. Introduction
- 13.3.2. Key Region-Specific Dynamics
- 13.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
- 13.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
- 13.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 13.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 13.3.6.1. Germany
- 13.3.6.2. The U.K.
- 13.3.6.3. France
- 13.3.6.4. Italy
- 13.3.6.5. Spain
- 13.3.6.6. Rest of Europe
- 13.4. South America
- 13.4.1. Introduction
- 13.4.2. Key Region-Specific Dynamics
- 13.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
- 13.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
- 13.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 13.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 13.4.6.1. Brazil
- 13.4.6.2. Argentina
- 13.4.6.3. Rest of South America
- 13.5. Asia-Pacific
- 13.5.1. Introduction
- 13.5.2. Key Region-Specific Dynamics
- 13.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
- 13.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
- 13.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 13.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 13.5.6.1. China
- 13.5.6.2. India
- 13.5.6.3. Japan
- 13.5.6.4. Australia
- 13.5.6.5. Rest of Asia-Pacific
- 13.6. Middle East and Africa
- 13.6.1. Introduction
- 13.6.2. Key Region-Specific Dynamics
- 13.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
- 13.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
- 13.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
14. Competitive Landscape
- 14.1. Competitive Scenario
- 14.2. Market Share Analysis
- 14.3. Mergers and Acquisitions Analysis
15. Company Profiles
- 15.1. Pfizer, Inc.*
- 15.1.1. Company Overview
- 15.1.2. Product Portfolio and Description
- 15.1.3. Financial Overview
- 15.1.4. Key Developments
- 15.2. Sanofi
- 15.3. GlaxoSmithKline plc
- 15.4. Cumberland Pharmaceuticals, Inc.
- 15.5. Actelion Pharmaceuticals, Inc. (Johnson & Johnson)
- 15.6. Boehringer Ingelheim International GmbH (C.H. Boehringer Sohn Ag & Co. KG)
- 15.7. Corbus Pharmaceuticals Holdings, Inc.
- 15.8. Bayer AG
- 15.9. Gilead Sciences, Inc.
- 15.10. Allergan, Inc. (Abbvie)
LIST NOT EXHAUSTIVE
16. Appendix
- 16.1. About Us and Services
- 16.2. Contact Us
